Bruce Eaton - Mar 2, 2023 Form 4 Insider Report for Editas Medicine, Inc. (EDIT)

Role
EVP, CBO AND CTO
Signature
/s/ Bruce Eaton
Stock symbol
EDIT
Transactions as of
Mar 2, 2023
Transactions value $
-$898
Form type
4
Date filed
3/6/2023, 03:30 PM
Previous filing
Feb 15, 2023
Next filing
May 11, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction EDIT Common Stock Award $0 +16.7K +27.38% $0.00 77.7K Mar 2, 2023 Direct F1
transaction EDIT Common Stock Sale -$898 -101 -0.13% $8.89 77.6K Mar 3, 2023 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction EDIT Stock Option (right to buy) Award $0 +50K $0.00 50K Mar 2, 2023 Common Stock 50K $8.72 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The common stock received by the Reporting Person was in connection with the grant of a restricted stock unit award to the Reporting Person, for no consideration, and which is scheduled to vest over four years with 25% of the units vesting on March 2, 2024 and the remaining 75% of the units scheduled to vest in equal quarterly installments thereafter through March 2, 2027.
F2 Sale was effected pursuant to a durable automatic sales instruction plan adopted by the Reporting Person on June 15, 2019, and represents the sale of shares by the Issuer necessary to meet tax withholding obligations as a result of vesting in restricted stock units on March 2, 2023. The sale does not represent a discretionary trade by the Reporting Person.
F3 This option was granted on March 2, 2023 and is scheduled to vest over four years in equal monthly installments beginning on April 2, 2023 through March 2, 2027.